Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD

The two main subsets of nonalcoholic fatty liver disease (NAFLD) include: (1) nonalcoholic fatty liver (NAFL), the more common and non-progressive subtype; and (2) nonalcoholic steatohepatitis (NASH), the less common subtype, which has the potential to progress to advanced liver damage. Current trea...

詳細記述

保存先:
書誌詳細
主要な著者: Pratima Dibba, Andrew A. Li, Brandon J. Perumpail, Nimy John, Sandy Sallam, Neha D. Shah, Waiyee Kwong, George Cholankeril, Donghee Kim, Aijaz Ahmed
フォーマット: Artigo
言語:Inglês
出版事項: MDPI AG 2018-09-01
シリーズ:Diseases
主題:
NAFLD
NASH
nonalcoholic fatty liver disease
drug therapy
chemokine receptor 2 and 5
galectin-3 protein
toll-like receptor 4
fibroblast growth factor 19
selective thyroid hormone receptor-beta
apoptosis signal-regulating kinase 1
acetyl-coenzyme A carboxylase
farnesoid X receptor
inflammasomes
オンライン･アクセス:http://www.mdpi.com/2079-9721/6/3/83
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料